Pfizer (NYSE:PFE) Stock Price Down 1.7% – What’s Next?

by · The Cerbat Gem

Pfizer Inc. (NYSE:PFE – Get Free Report) shares were down 1.7% during mid-day trading on Monday . The stock traded as low as $25.23 and last traded at $25.3050. Approximately 53,073,677 shares traded hands during mid-day trading, an increase of 3% from the average daily volume of 51,385,086 shares. The stock had previously closed at $25.74.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Guggenheim upped their price target on shares of Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley lowered their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.39.

Check Out Our Latest Research Report on Pfizer

Pfizer Stock Down 1.7%

The stock has a market capitalization of $143.88 billion, a price-to-earnings ratio of 13.46, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The firm has a 50-day moving average of $25.01 and a 200 day moving average of $24.60. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Institutional Trading of Pfizer

A number of large investors have recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the 1st quarter worth approximately $27,000. Curio Wealth LLC lifted its holdings in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter valued at about $28,000. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer during the third quarter worth about $29,000. Finally, Harbor Asset Planning Inc. bought a new stake in Pfizer in the second quarter worth about $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also